Want to see ALGS full AI Analyst Report?
Top Page
Aligos Therapeutics
(NASDAQ:ALGS)
Select Model
Select Model
Rating:41Neutral
Price Target:
$5.00
▼(-33.07% Downside)
Action:Reiterated
Date:09/13/26
ALGS scores low primarily due to weak financial performance (persistent losses, declining revenue, and heavy ongoing cash burn) and bearish technical trends (price below key moving averages with negative MACD). Corporate governance actions provide only modest support, while valuation is constrained by negative earnings and no dividend data.
Positive Factors
High Gross Margin
The roughly 89% TTM gross margin indicates that reported revenue carries substantial economic value before operating expenses. If the company scales revenue from future products or collaborations, this margin profile could support better operating leverage, although current revenue remains limited.
Negative Factors
Persistent Losses and Revenue Decline
Recurring operating and net losses show that the current expense base is far too large for the company’s revenue scale. The approximately 20.5% TTM revenue decline further weakens operating leverage, making a durable path to profitability dependent on stronger future development or commercial outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
The roughly 89% TTM gross margin indicates that reported revenue carries substantial economic value before operating expenses. If the company scales revenue from future products or collaborations, this margin profile could support better operating leverage, although current revenue remains limited.
Read all positive factors
Aligos Therapeutics (ALGS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.28M
Dividend YieldN/A
Average Volume (3M)103.48K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth893.01%
EPS Growth41.74%
CountryUS
Employees82
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.30
Shares Outstanding5,444,558
10 Day Avg. Volume34,686
30 Day Avg. Volume103,484
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.72
Price to Sales (P/S)42.14
P/FCF Ratio-1.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$72.50Price Target Upside870.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.3
Revenue Forecast (FY)$35.99M
Aligos Therapeutics Business Overview & Revenue Model
Company Description
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-ant...
How the Company Makes Money
As a clinical-stage company, Aligos Therapeutics has not historically generated recurring revenue from product sales because it does not have approved therapies commercialized. Its cash inflows have primarily come from financing activities (such a...
Aligos Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.52M | 2.19M | 3.94M | 15.53M | 13.91M | 4.36M |
| Gross Profit | 31.26M | 1.26M | 3.94M | 15.53M | 13.91M | 4.36M |
| EBITDA | -71.19M | -22.95M | -128.26M | -83.81M | -92.27M | -124.41M |
| Net Income | -75.96M | -24.19M | -131.21M | -87.68M | -96.05M | -128.33M |
Balance Sheet | ||||||
| Total Assets | 66.33M | 88.53M | 70.09M | 151.53M | 146.69M | 235.37M |
| Cash, Cash Equivalents and Short-Term Investments | 30.38M | 77.84M | 56.94M | 135.70M | 125.83M | 190.73M |
| Total Debt | 3.50M | 5.25M | 8.38M | 11.14M | 12.57M | 14.46M |
| Total Liabilities | 34.44M | 34.99M | 99.07M | 59.45M | 42.79M | 50.64M |
| Stockholders Equity | 31.88M | 53.55M | -28.97M | 92.08M | 103.90M | 184.73M |
Cash Flow | ||||||
| Free Cash Flow | -94.52M | -82.94M | -80.87M | -79.02M | -80.33M | -116.55M |
| Operating Cash Flow | -94.17M | -82.50M | -80.74M | -79.00M | -79.39M | -115.66M |
| Investing Cash Flow | 105.59M | -37.83M | -18.28M | 44.98M | -26.29M | 3.02M |
| Financing Cash Flow | 228.00K | 101.64M | 355.00K | 88.33M | 164.00K | 78.68M |
Aligos Therapeutics Technical Analysis
Negative
7.47
Price Trends
5.80
Negative
5.76
Negative
6.97
Negative
Market Momentum
-0.29
Positive
40.46
Neutral
21.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Negative. The current price of 7.47 is above the 20-day moving average (MA) of 6.02, above the 50-day MA of 5.80, and above the 200-day MA of 6.97, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 40.46 is Neutral, neither overbought nor oversold. The STOCH value of 21.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALGS.
Aligos Therapeutics Risk Analysis
Aligos Therapeutics disclosed 91 risk factors in its most recent earnings report. Aligos Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aligos Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
ALGS
Aligos Therapeutics
5.24
-4.43
-45.81%
MNOV
Medicinova
3.32
2.05
161.42%
CELU
Celularity
1.31
-0.91
-40.99%
GNTA
Genenta Science SpA Sponsored ADR
0.70
-2.16
-75.49%
ACRV
Acrivon Therapeutics, Inc.
1.85
0.22
13.50%
Aligos Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Aligos Therapeutics Shareholders Approve Directors and Governance Changes
Positive
Jun 26, 2026
On June 25, 2026, Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders, at which investors elected two Class III directors, Bridget Martell and Carole Nuechterlein, to serve until the 2029 annual meeting or until their successors are ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.